Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer

Dr Michael Cecchini  speaks to ecancer about telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with bevacizumab vs standard of care in patients with 3L+ colorectal cancer. In this phase I study of patients with heavily pretreated advanced colorectal cancer, the antibody-drug conjugate Temab-A targeting c-Met, combined with bevacizumab, demonstrated encouraging anti-tumour activity with a manageable safety profile. Dr Cecchini highlights that the 2.4 mg/kg Temab-A dose plus bevacizumab achieved a confirmed objective response rate of 26.7% compared with 0% with standard-of-care trifluridine/tipiracil plus bevacizumab. Disease control rates were also substantially higher with Temab-A combination therapy, supporting its potential as a novel therapeutic option in third-line or later treatment settings.